SCLC, Extensive Stage
38 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Molecular Subtyping of Extensive Stage Small Cell Lung Cancer and Relevent Clinical Significance (NCT05933863) | Peking University Cancer Hospital & Institute | 2022-03-29 |
| Utidelone in Third-line and Above Treatment of Small Cell Lung Cancer (NCT05299255) | Henan Cancer Hospital | 2021-09-05 |
| Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer (NCT04660097) | Henan Cancer Hospital | 2021-05-20 |
| Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC (NCT05116007) | Akeso | 2021-03-29 |
| Lung Cancer Registry (NCT04654364) | Arbeitsgemeinschaft medikamentoese Tumortherapie | 2020-08-18 |
| Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide (NCT04221529) | AIO-Studien-gGmbH | 2020-01-06 |
| Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer (NCT04731909) | Third Military Medical University | 2018-10-01 |
Track SCLC, Extensive Stage automatically
Every clearance here is in the API, with alerts when new ones post.